Daré Bioscience Releases New CEO Corner Episode
The company's latest video features CEO Sabrina Martucci Johnson discussing its ongoing product and clinical efforts.
Updated on Nov. 9, 2026 in Lifestyle

Daré Bioscience released the next episode in its CEO Corner video series on November 9, 2026. The episode features Founder, President and CEO Sabrina Martucci Johnson and is accessible at darebioscience.com/ceocorner.
Why it matters
The release gives investors and the public a direct update from company leadership on its product pipeline and commercial plans. The company also reports that prescription dispensing of its DARE to PLAY Sildenafil Cream is expected to begin this quarter.
The episode remains accessible for approximately 90 days after release at darebioscience.com/ceocorner. DARE to PLAY Sildenafil Cream is a 503B compounded product, and compounded drug products are not approved by the FDA.
The players
Daré Bioscience
Daré Bioscience is a Nasdaq-listed health biotech company (NASDAQ: DARE) headquartered in San Diego that develops women's health products.
Sabrina Martucci Johnson
Sabrina Martucci Johnson is the founder, president and chief executive officer of Daré Bioscience and leads the company's product development efforts.
The details
The episode is released as a video in the company's CEO Corner series and hosted on its website. Daré Bioscience is a Nasdaq-listed health biotech company (NASDAQ: DARE) based in San Diego, and FloraSync LF5 is now available.
Timeline
November 9, 2026: CEO Corner episode released.
This quarter: DARE to PLAY Sildenafil Cream prescription dispensing expected to begin.
Approximately 90 days after release: CEO Corner episode no longer accessible.
Sex Life
DARE to PLAY Sildenafil Cream is sold under the 503B compounding pathway established by the Drug Quality and Security Act, which allows outsourcing facilities to produce compounded drugs without individual FDA approval. Compounded products therefore reach patients without the clinical review that governs approved drugs.
Readers considering DARE to PLAY Sildenafil Cream should note that it is a 503B compounded product and is not FDA-approved. Compounded medications may differ from approved versions in formulation and oversight, so questions about suitability should be directed to a licensed clinician.
The takeaway
Compounded products offer access to treatments outside the FDA approval process, which means patients should confirm sourcing and clinical oversight before starting therapy. Reviewing the company's own materials alongside guidance from a healthcare provider can help inform that decision.
What happens next
DARE to PLAY Sildenafil Cream prescription dispensing is expected to begin this quarter, and the CEO Corner episode will remain accessible for approximately 90 days after its November 9, 2026 release.
Further reading
Explore more Sex Life coverage for context on sexual health products and treatments.






